患有多发性硬化症的患者的神经病变,接受 Teriflunomide 治疗
Ahmet Kasim Kilic1, Aysegul Akkan Suzan1, Anil Bulut1
1University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Department of Neurology - Istanbul, Turkey.
概括
多发性硬化症的特里弗卢诺米德治疗可能会导致周围神经病变. 神经传导研究显示,在服用特里弗卢诺米德的患者中出现了显著异常,在切换疗法后反转.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 特里弗卢诺胺是一种治疗多发性硬化症的口服药物.
- 它抑制了新的皮里米丁合成,导致细胞循环停止.
- 周围神经病变是一种罕见的潜在副作用.
研究的目的:
- 为了调查治疗teriflunomide的患者中外围神经病变的发生情况.
- 评估Teriflunomide使用者的神经导电与其他治疗方法和健康对照组相比.
主要方法:
- 在42名多发性硬化症患者接受特里弗卢诺米德治疗,18名接受其他疾病修饰疗法和25名健康对照者的横截面研究.
- 对多个外围神经进行神经学检查和神经传导研究.
- 在2020年1月至2021年期间收集的数据.
主要成果:
- 用户Teriflunomide显示显著减缓表面经神经传导速度和更长的远端延迟.
- 泰里弗卢诺米德患者表现出较低的表面经神经动作潜能幅度和经运动神经幅度.
- 在转换为替代疗法后,神经病症症状在10名患者中逆转.
结论:
- 泰里弗卢诺米德有可能诱导外围神经病变.
- 临床意识,症状评估和电诊断评估至关重要.
- 切换疗法可能会逆转 teriflunomide 诱导的神经病变.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Antiepileptic Drugs: Glutamate Antagonists
422
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
422
Parkinson's Disease: Treatment
299
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
299


